Opinion|Videos|April 25, 2025
Regulatory Challenges and Clinical Differentiators for Pediatric Atopic Dermatitis Treatments
Author(s)Alexandra K. Golant, MD
Alexandra Golant, MD discusses how regulatory challenges, ethical considerations in pediatric clinical trials, and limited pharmacokinetic data present significant hurdles for pediatric treatment approvals, while topical ruxolitinib cream's targeted mechanism of action and steroid-sparing benefits make it a meaningful addition for younger children.
Advertisement
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- What are some of the biggest hurdles in getting new pediatric treatments approved, and what would make topical ruxolitinib cream stand out as a meaningful addition in younger children?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
